Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-02-13
2007-02-13
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252140, C514S269000, C514S275000, C514S326000, C540S553000, C544S298000, C544S331000, C544S332000, C546S210000
Reexamination Certificate
active
10472236
ABSTRACT:
An aryl-substituted alicyclic compound of the formula (I):wherein U is 1,4,5,6-tetrahydropyrimidin-2-yl, etc., A is phenylene, etc., B is piperidine-1,4-diyl, etc., Z is —CONH—, etc., R3is hydrogen, etc., R5is hydrogen, aryl, etc., R6is a mono-substituted amino (e,g., benzyloxycarbonylamino), R7is hydrogen, etc., and a process for preparation thereof, and a pharmaceutical composition containing the same. The compound of the present invention has a high selectivity for αvβ3 integrin, and exhibits a potent inhibitory activity thereto, and hence, it is useful as a preventive or/and a therapeutic agent for a disease in which αvβ3 integrin is involved.
REFERENCES:
patent: 5990145 (1999-11-01), Wehner et al.
patent: 6451800 (2002-09-01), Ajito et al.
patent: 1074543 (2001-02-01), None
patent: 98/18461 (1998-05-01), None
patent: 00/06169 (2000-02-01), None
patent: 01/44230 (2001-06-01), None
patent: 01/96334 (2001-12-01), None
Agrez et al., The alpha-v-beta-6 Integrin induces gelatinase B secretion in colon cancer cells, Int. J. Cancer, 81, pp. 90-97, 1999.
Brooks et al., Integrin alpha-v-beta-3: A therapeutic target, DN&P, 10(8), pp. 456-461, Oct. 1997.
Gladson et al., Vitronectin Expression in Differentiating Neuroblastic Tumors, American Journal of Pathology, vol. 150, No. 5, pp. 1631-1646, May 1997.
Kim et al., Vitronectin-driven Human Keratinocyte Locomotion Is Mediated by the alpha-v-beta-5 Integrin Receptor, The Journal of Biological Chemistry, vol. 269, No. 43, pp. 26928-26932, Oct. 1994.
Nip et al., The role of the Integrin vitronectin receptor, alpha-v-beta-3 in melanoma metastasis, Cancer and Metastasis Reviews, 14, pp. 241-252, 1995.
Raynal et al., Bone Sialoprotein Stimulates in vitro Bone Resorption, Endocrinology, vol. 137, No. 6, pp. 2347-2354, 1996.
Schvartz et al., Vitronectin, The International Journal of Biochemistry & Cell Biology, 31, pp. 539-544, 1999.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Antonov et al., Medline Abstract (American Journal of Pathology, vol. 165, Issue 1, pp. 247-258) Jul. 2004.
Douglas, Jr. Introduction to Viral Diseases, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1739-1747, 1996.
West, Solid Solutions, Solid state chemistry and it's applications, Wiley, New York, pp. 358 and 365, 1988.
Vippagunta et al., Crystalline solids, Advanced Drug Delivery Reviews, 48 (2001), pp. 3-26, 2001.
J. Samanen et al., “Vascular Indications for Integrin αv Antagonists”, Current Pharmaceutical Design, vol. 3, pp. 545-583, 1997.
W. Miller et al., “Identification andin vivoefficacy of small-molecule antagonists of integrin αvβe(the vitronectin receptor)”, Drug Discovery Today, vol. 5, No. 9, pp. 397-408, 2000.
G. P. Curley et al., “Integrin Antagonists”, Cell. Mol. Life Sci., vol. 56, pp. 427-441, 1999.
Iwama Seiji
Kitano Tomoko
Morie Toshiya
Notake Mitsue
Dainippon Pharmaceutical Co., Ltd.
Rao Deepak
LandOfFree
Aryl-substituted alicyclic compound and medical composition... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl-substituted alicyclic compound and medical composition..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl-substituted alicyclic compound and medical composition... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3892164